Century Therapeutics Inc. is a cell therapy company. It involved in developing induced pluripotent stem cell -derived cell therapies in immuno-oncology. Century Therapeutics Inc. is based in PHILADELPHIA.
| Revenue (Most Recent Fiscal Year) | $109.16M |
| Net Income (Most Recent Fiscal Year) | $-9.58M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.64 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 158.65 |
| Pre-Tax Margin (Trailing 12 Months) | -8.84% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -49.51% |
| Return on Assets (Trailing 12 Months) | -38.09% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.28 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.28 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.28 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.17 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.14 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.93 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 181.07M |
| Free Float | 176.73M |
| Market Capitalization | $382.07M |
| Average Volume (Last 20 Days) | 0.45M |
| Beta (Past 60 Months) | 1.59 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 50.20% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |